VEGF receptor 2 blockade leads to renal cyst formation in mice

Slides:



Advertisements
Similar presentations
Volume 72, Issue 2, Pages (July 2007)
Advertisements

Volume 72, Issue 7, Pages (October 2007)
Volume 70, Issue 1, Pages (July 2006)
Volume 65, Issue 1, Pages (January 2004)
Increased expression of heparanase in overt diabetic nephropathy
Diabetic Albuminuria Is Due to a Small Fraction of Nephrons Distinguished by Albumin- Stained Tubules and Glomerular Adhesions  Patricia M. Kralik, Yunshi.
Volume 64, Issue 6, Pages (December 2003)
Volume 85, Issue 4, Pages (April 2014)
Mutagenesis of the epithelial polarity gene, discs large 1, perturbs nephrogenesis in the developing mouse kidney  Eman Naim, Alan Bernstein, John F.
Volume 71, Issue 3, Pages (February 2007)
Volume 72, Issue 4, Pages (August 2007)
Volume 72, Issue 6, Pages (September 2007)
Volume 83, Issue 1, Pages (January 2013)
Volume 83, Issue 5, Pages (May 2013)
Volume 65, Issue 1, Pages (January 2004)
Volume 85, Issue 2, Pages (January 2014)
Volume 61, Issue 5, Pages (May 2002)
Volume 84, Issue 5, Pages (November 2013)
Volume 59, Issue 1, Pages (January 2001)
Volume 69, Issue 1, Pages (January 2006)
Volume 59, Issue 5, Pages (May 2001)
Volume 71, Issue 8, Pages (April 2007)
A new mouse model of immune-mediated podocyte injury
Volume 81, Issue 9, Pages (May 2012)
Yang Wang, Yi Ping Wang, Yuet-Ching Tay, David C.H. Harris 
Role of meprin A in renal tubular epithelial cell injury
Volume 88, Issue 5, Pages (November 2015)
Volume 70, Issue 8, Pages (October 2006)
PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice
Oliver Vonend, Clare M. Turner  Kidney International 
Volume 63, Issue 4, Pages (April 2003)
Volume 70, Issue 1, Pages (July 2006)
Volume 72, Issue 3, Pages (August 2007)
Yongji Wang, Megan L. Borchert, Hector F. DeLuca  Kidney International 
Volume 70, Issue 2, Pages (July 2006)
Volume 65, Issue 1, Pages (January 2004)
Akira Shimizu, Kazuhiko Yamada, David H. Sachs, Robert B. Colvin 
Prevention of mesangial sclerosis by bone marrow transplantation
Volume 53, Issue 5, Pages (May 1998)
Volume 61, Issue 6, Pages (June 2002)
The L1 cell adhesion molecule is a potential biomarker of human distal nephron injury in acute tubular necrosis  Y. Allory, V. Audard, P. Fontanges, P.
Volume 71, Issue 7, Pages (April 2007)
Volume 82, Issue 2, Pages (July 2012)
Only anti-CD133 antibodies recognizing the CD133/1 or the CD133/2 epitopes can identify human renal progenitors  Maria L. Angelotti, Elena Lazzeri, Laura.
Volume 74, Issue 6, Pages (September 2008)
Volume 82, Issue 3, Pages (August 2012)
Volume 69, Issue 2, Pages (January 2006)
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis  H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo 
Volume 72, Issue 7, Pages (October 2007)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Volume 80, Issue 5, Pages (September 2011)
Volume 72, Issue 2, Pages (July 2007)
Volume 85, Issue 1, Pages (January 2014)
Volume 69, Issue 11, Pages (June 2006)
Volume 71, Issue 7, Pages (April 2007)
Recapitulation of phylogeny by ontogeny in nephrology
Volume 60, Issue 5, Pages (November 2001)
TGF-β type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glomerulonephritis  C.Y. Song, B.C. Kim, H.K. Hong,
Volume 73, Issue 6, Pages (March 2008)
Volume 70, Issue 2, Pages (July 2006)
Volume 69, Issue 3, Pages (February 2006)
Volume 80, Issue 10, Pages (November 2011)
Volume 62, Issue 1, Pages (July 2002)
Volume 75, Issue 3, Pages (February 2009)
Volume 74, Issue 9, Pages (November 2008)
Volume 72, Issue 11, Pages (December 2007)
J. Ma, A. Weisberg, J.P. Griffin, D.E. Vaughan, A.B. Fogo, N.J. Brown 
Volume 70, Issue 9, Pages (November 2006)
Volume 79, Issue 11, Pages (June 2011)
Presentation transcript:

VEGF receptor 2 blockade leads to renal cyst formation in mice S. McGrath-Morrow, C. Cho, R. Molls, M. Burne-Taney, M. Haas, D.J. Hicklin, R. Tuder, H. Rabb  Kidney International  Volume 69, Issue 10, Pages 1741-1748 (May 2006) DOI: 10.1038/sj.ki.5000314 Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 1 Cyst development in 2- and 3-week-old kidney from mice treated with DC101 in the perinatal period. (a–f) Multiple cysts (a, b) developed in 2-week-old DC101-treated kidney. In 3-week-old DC101-treated kidney (d, e), cysts were significantly larger, black arrow points to abnormal glomerulus and orange arrow points to cellular infiltrates. (g) Two- and 3-week-old DC101-treated kidney had significantly larger cysts then 2- and 3-week-old control mice (*,**P<0.0001). Three-week-old DC101-treated kidney had significantly larger cysts then 2-week-old DC101-treated kidney (‡P<0.001). (h) Renal cysts number was significantly larger in 2- and 3-week-old DC101-treated kidney compared to 2- and 3-week-old control kidney (*,**P<0.0001). Comparisons of the means were done by one-way analysis of variance, n=5–9, data on the y-axis is expressed in arbitrary units. Kidney International 2006 69, 1741-1748DOI: (10.1038/sj.ki.5000314) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 2 Localization of DC101 to glomeruli in 5-day-old kidney. DC101 antibodies were injected into 5-day-old mice. Cryostat sections were co-stained to detect DC101 localization (g, h, i, red staining) and synaptopodin (d, e, f, green staining). At 2 h, DC101 antibody staining was found primarily in the glomeruli (white arrows). Although control kidney had glomerular staining (f), no significant DC101 antibody staining was detected (i). Nuclei were stained blue with 4′,6-diamidino-2-phenylindole dihydrochloride (a– c – merged figures). Kidney International 2006 69, 1741-1748DOI: (10.1038/sj.ki.5000314) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 3 PAS and ACE staining in mice treated with DC101 in the perinatal period. (a–d) A subgroup of cysts stained positive for PAS in both 2- and 3-week-old kidney treated with perinatal DC101 (a, c), black arrow. The largest cysts had little or no PAS staining (*). Some tubules had protein resorption droplets (red arrow). Cysts were not present in 2- and 3-week-old control kidney (b, d); however, PAS staining was present in the brush borders of the proximal tubules. (e–h) ACE staining was present in proximal tubules of DC101-treated (e, f) and control kidney at 1 and 2 weeks of age (g, h). Note at 1 week, ACE staining is present in mildly dilated proximal tubule of DC101-treated-kidney (white arrow). At 2 weeks, some dilated renal cysts have increased ACE staining (white arrow). Kidney International 2006 69, 1741-1748DOI: (10.1038/sj.ki.5000314) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 4 Abnormal glomeruli in mice treated with perinatal DC101. (a, b) One-week-old DC101-treated kidney with enlarged, hypocellular glomeruli (a), black arrow and small immature glomeruli near capsule, yellow arrows. (c–f) Abnormal glomeruli in 2- and 3-week old DC101-treated kidney (c, e), black arrows. Red arrows point to normal glomeruli in control kidney (b, d, f). Kidney International 2006 69, 1741-1748DOI: (10.1038/sj.ki.5000314) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 5 Increased urine protein in 3-week-old mice treated with DC101 in the perinatal period. (a) Three-week-old DC101-treated mice had significantly more urine protein then 2-week-old DC101-treated and 2-and 3-week-old control mice. (b) There was no significant difference in serum creatinine between 2- and 3-week-old DC101-treated and 2- and 3-week-old control mice. (c) Kidney from 3-week-old DC101-treated mice had a paler appearance then the 3-week-old control kidney. Kidney International 2006 69, 1741-1748DOI: (10.1038/sj.ki.5000314) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 6 Increased mortality in mice treated with both DC101 and MF1 in the perinatal period. (a–c) Mice treated with MF1 antibody in the perinatal period did not develop renal cysts (a). In contrast, mice treated with both DC101+MF1(D+M) in the perinatal period developed renal cysts at 2 and 3 weeks of age (b, c). (d) At 1 week of age, D+M-treated mice had significantly greater mortality compared to control mice (*P<0.006). At 2 weeks of age, D+M mice had significantly greater mortality compared to control mice and DC101-treated mice (**P<0.0001). n=15–40 animals/group for 1 and 2 weeks time points. Comparisons of the means were done by one-way analysis of variance. Kidney International 2006 69, 1741-1748DOI: (10.1038/sj.ki.5000314) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 7 Increased proliferation in renal cysts of mice treated with perinatal DC101. (a–f) Black arrows point to Ki67 staining in DC101-treated mice at 1, 2, and 3 weeks of age (a, c, e). Control kidney had less Ki67 staining of renal tubules (b, d, f). (g) DC101-treated kidney at 1, 2, and 3 weeks of age had significantly more Ki67 staining then 1-, 2- and 3-week-old control kidney (*P<0.01, **P<.004 and ***P<0.01, respectively) by Student's t-test, n=3–4. Kidney International 2006 69, 1741-1748DOI: (10.1038/sj.ki.5000314) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 8 No difference in VEGF protein levels between DC101-treated and control kidney. Equal amounts of kidney homogenates were loaded in each lane. No differences in VEGF protein levels were found between DC101-treated and control kidneys at 1, 2, or 3 weeks of age. Kidney International 2006 69, 1741-1748DOI: (10.1038/sj.ki.5000314) Copyright © 2006 International Society of Nephrology Terms and Conditions